“We recognize that those with rare diseases often have complex needs that go unmet by traditional assistance,” said Green.

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...

Abstract Title: Briquilimab Potently Inhibits Stem Cell Factor (SCF)/c-Kit Signaling and Induces Mast Cell Apoptosis Poster Number: 541 Session Title: Novel Mechanisms of Mast Cells, Basophils and IgE ...

Hives (urticaria) are a common skin reaction that causes bumps, raised patches, or both. They are one way the body responds to an allergen or trigger. Reactions can be uncomfortable but aren’t ...

A spirometry test is one way to distinguish the type of lung disease. Emphysema and chronic bronchitis are both long-term lung conditions. They’re part of a disorder known as chronic obstructive ...

Angioedema is a well-known side effect of treatment with an angiotensin-converting enzyme (ACE) inhibitor and one that we have been willing to accept in view of the incidence of the problem and ...

Fibromyalgia (FMS) and chronic fatigue syndrome (CFS), also called myalgic encephalomyelitis (ME/CFS), are chronic conditions that have similar symptoms. Both cause extreme tiredness, which could ...

The National Institute of Mental Health defines chronic disease as “a condition that lasts at least one year and requires ongoing medical attention or limits activities of daily living or both.” ...

Patients with chronic spontaneous urticaria see well ... Lanadelumab increases attack-free rates in hereditary angioedema patients Lanadelumab effectively improved attack-free rates of type ...

A study suggests that catching COVID-19 significantly raises the risk of developing ME/CFS (formerly called "chronic fatigue syndrome"), a typically lifelong condition that can be debilitating.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...